Merck acquired all the outstanding equity of NovaCardia for a total purchase price of $366.4 million (including $16.4 million of cash and investments on hand at closing), which was paid through the issuance of 7.3 million shares of Merck & Co., Inc. common stock to the former NovaCardia shareholders. Approximately $325 million of the purchase price will be accounted for as in-process research and development costs, which is expected to result in a charge to Merck's third quarter earnings of 15 cents per share.
Merck will provide further details about its third quarter financial performance as well as its full year guidance as part of the Company's regular third quarter earnings release on Oct. 22, 2007.
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.